Cardio-fitness cuts death and disease by nearly 20%

Running, cycling, or swimming – if you regularly exercise, you’re well on track for a long and healthy life, as groundbreaking new research from the University of South Australia finds that an increased cardio fitness level will reduce your risk of death from any cause by 11-17%. Published in BJSM, the study found that for every 1-MET increase in cardiorespiratory fitness

Read More


New research finds half-cardio, half-strength training reduces cardiovascular disease risks

Approximately one in three deaths in the U.S. is caused by cardiovascular disease, according to the U.S. Centers for Disease Control and Prevention. A robust body of evidence shows aerobic exercise can reduce risks, especially for people who are overweight or obese. But few studies have compared results with resistance exercise — also known as strength

Read More


Cordio HearO® system an AI phone app detects worsening heart failure based on changes in patients’ voices

A smartphone app using artificial intelligence technology to detect changes in the voice of a person with heart failure predicted more than 75% of hospitalizations about three weeks before they happened, according to late-breaking science presented Nov. 13 at the American Heart Association’s Scientific Sessions 2023. The meeting, held Nov. 11–13, in Philadelphia, is a premier global exchange

Read More


Ground-breaking discovery could pave the way for new therapies to prevent cardiovascular disease and stroke

Researchers at the University of Leicester have discovered the mechanism by which cholesterol in our diet is absorbed into our cells. This discovery, which has just been published in the journal Science opens up new opportunities for therapeutic intervention to control cholesterol uptake that could complement other therapies and potentially save lives. The research, conducted with colleagues

Read More


Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events

Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine At the American Heart Asoociation annual Scientific Session were announced the primary results of SELECT, its landmark phase 3 cardiovascular outcomes trial investigating the effects of once-weekly semaglutide 2.4 mg (Wegovy®) in

Read More


Leading cardiologists reveal new heart disease risk calculator

Cardiovascular, kidney and metabolic health measures included in new PREVENT risk calculator, detailed in a new American Heart Association Scientific Statement Statement Highlights: A new calculator estimates a person’s risk for cardiovascular disease (CVD) over the next 30 years by combining measures of cardiovascular, kidney and metabolic health for the first time, according to a

Read More